Roche Reports P-II Study (FENopta) Results of Fenebrutinib for the Treatment of Multiple Sclerosis
Shots:
- The P-II study (FENopta) evaluating the efficacy, safety, and PK of fenebrutinib (BTK inhibitor) vs PBO in 109 adults aged 18-55yrs. with RMS
- The trial met 1EPs & 2EPs i.e., patients achieved a reduction in MRI markers of MS disease activity in the brain, reduction in the total no. of new gadolinium-enhancing T1 brain lesions & new or enlarging T2 brain lesions. The safety profile was consistent with previous and ongoing clinical trials & no new safety concerns were reported
- Additionally, fenebrutinib was found to be potent and highly selective in pre-clinical studies. The P-III clinical trial program of fenebrutinib is ongoing for RMS and primary progressive MS (PPMS)
Ref: Globenewswire | Image: Roche
Related News:- Roche Expands its MS Portfolio with the Initiation of P-III Clinical Program of Fenebrutinib and Ocrevus (ocrelizumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
